NOXXON Reports H1 2021 Financial Results and Provides Business Update

Positive results from two cohorts of Phase 1/2 clinical trial with NOX-A12 in brain cancer; full readout expected in Q1 2022
Appointment of Scientific Advisory Board with top US and EU pancreatic cancer experts
Appointment of 3 new Supervisory Board members with remarkable experience
Strengthening the Company’s balance sheet by raising a total of €9.3 million ensuring financial visibility into June 2022

BERLIN, October 22, 2021–(BUSINESS WIRE)–Regulatory News:

NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announces its financial results and business highlights for the six months ending June 30, 2021, and provides an outlook for the rest of the year.

Aram Mangasarian, CEO of NOXXON commented: “I am delighted to report on the strong progress NOXXON has made in 2021 so far by delivering on its unique approach to target the…